tiprankstipranks
Trending News
More News >
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (DE:818)
:818

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818) Price & Analysis

Compare
0 Followers

818 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

2.01%97.71%
Insiders
2.01%
Mutual Funds
― Other Institutional Investors
97.71% Public Companies and
Individual Investors

818 FAQ

What was Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price range in the past 12 months?
Zylox-Tonbridge Medical Technology Co., Ltd. Class H lowest stock price was €1.06 and its highest was €2.28 in the past 12 months.
    What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap?
    Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s market cap is €750.00M.
      When is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date?
      Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2025 which is in 90 days.
        How were Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s earnings last quarter?
        Zylox-Tonbridge Medical Technology Co., Ltd. Class H released its earnings results on Mar 20, 2025. The company reported €0.012 earnings per share for the quarter, beating the consensus estimate of N/A by €0.012.
          Is Zylox-Tonbridge Medical Technology Co., Ltd. Class H overvalued?
          According to Wall Street analysts Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Zylox-Tonbridge Medical Technology Co., Ltd. Class H pay dividends?
            Zylox-Tonbridge Medical Technology Co., Ltd. Class H pays a Notavailable dividend of €0.012 which represents an annual dividend yield of N/A. See more information on Zylox-Tonbridge Medical Technology Co., Ltd. Class H dividends here
              What is Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate?
              Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Zylox-Tonbridge Medical Technology Co., Ltd. Class H have?
              Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 322,400,760 shares outstanding.
                What happened to Zylox-Tonbridge Medical Technology Co., Ltd. Class H’s price movement after its last earnings report?
                Zylox-Tonbridge Medical Technology Co., Ltd. Class H reported an EPS of €0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.646%.
                  Which hedge fund is a major shareholder of Zylox-Tonbridge Medical Technology Co., Ltd. Class H?
                  Currently, no hedge funds are holding shares in DE:818

                  Company Description

                  Zylox-Tonbridge Medical Technology Co., Ltd. Class H

                  Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.

                  818 Stock 12 Month Forecast

                  Average Price Target

                  €2.10
                  ▼( -3.67% Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2023","6":"Jun<br/>2023","9":"Sep<br/>2023","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.4907692307692306,1.5415384615384615,1.5923076923076922,1.643076923076923,1.6938461538461538,1.7446153846153847,1.7953846153846154,1.8461538461538463,1.896923076923077,1.9476923076923076,1.9984615384615385,2.0492307692307694,{"y":2.1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.4907692307692306,1.5415384615384615,1.5923076923076922,1.643076923076923,1.6938461538461538,1.7446153846153847,1.7953846153846154,1.8461538461538463,1.896923076923077,1.9476923076923076,1.9984615384615385,2.0492307692307694,{"y":2.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.4907692307692306,1.5415384615384615,1.5923076923076922,1.643076923076923,1.6938461538461538,1.7446153846153847,1.7953846153846154,1.8461538461538463,1.896923076923077,1.9476923076923076,1.9984615384615385,2.0492307692307694,{"y":2.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.2,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.46,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.59,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.69,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.21,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.41,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.34,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.46,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.25,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.96,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.92,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.92,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CSPC Pharmaceutical Group
                  Tong Ren Tang Technologies Co
                  Wuxi Biologics (Cayman)
                  Top Education Group Ltd.
                  Shanghai Haohai Biological Technology Co., Ltd. Class H
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis